Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedFeb 07, 2026
DataAggregated Company Financials
Companies23
  • 7D1.9%
  • 3M11.7%
  • 1Y-1.4%
  • YTD3.1%

Over the last 7 days, the Pharma industry has risen 1.9%, driven by gains from Camurus of 2.8%. Meanwhile, Cessatech actually underperformed within the industry, shrinking 16% in the last week. Despite this gain, the industry's performance has been flat over the past year. Looking forward, earnings are forecast to grow by 35% annually.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 08 Feb 2026SEK 52.6bSEK 5.3b-SEK 1,403,945,157.0057.9x-37.5x9.9x
Tue, 06 Jan 2026SEK 49.5bSEK 5.3b-SEK 531,735,157.0071.7x-93.2x9.3x
Thu, 04 Dec 2025SEK 48.2bSEK 5.3b-SEK 531,735,157.0068.6x-90.7x9.1x
Sat, 01 Nov 2025SEK 51.4bSEK 5.2b-SEK 537,824,865.0074.7x-95.5x9.9x
Mon, 29 Sep 2025SEK 53.9bSEK 5.1b-SEK 405,183,865.0069.4x-133x10.6x
Wed, 27 Aug 2025SEK 56.9bSEK 5.1b-SEK 330,968,676.0080.2x-171.9x11.2x
Fri, 25 Jul 2025SEK 58.4bSEK 5.0b-SEK 375,088,364.0080.7x-155.7x11.6x
Sun, 22 Jun 2025SEK 49.7bSEK 4.8b-SEK 574,722,428.1266.9x-86.4x10.3x
Tue, 20 May 2025SEK 46.5bSEK 4.8b-SEK 600,998,711.4264.9x-77.4x9.6x
Thu, 17 Apr 2025SEK 44.1bSEK 4.7b-SEK 579,086,951.6067.7x-76.1x9.4x
Sat, 15 Mar 2025SEK 50.3bSEK 4.7b-SEK 809,594,236.1372.8x-62.1x10.7x
Mon, 10 Feb 2025SEK 52.0bSEK 4.4b-SEK 797,399,237.19132.7x-65.3x11.7x
Wed, 08 Jan 2025SEK 51.2bSEK 4.4b-SEK 615,811,189.66130.1x-83.2x11.5x
Fri, 06 Dec 2024SEK 49.8bSEK 4.4b-SEK 617,180,604.26135.8x-80.8x11.2x
Sun, 03 Nov 2024SEK 51.7bSEK 4.4b-SEK 682,051,223.43136.8x-75.8x11.9x
Tue, 01 Oct 2024SEK 65.2bSEK 5.9b-SEK 1,169,885,891.24170.2x-55.8x11.1x
Thu, 29 Aug 2024SEK 68.3bSEK 5.9b-SEK 918,264,100.4385.2x-74.4x11.6x
Sat, 27 Jul 2024SEK 67.9bSEK 5.6b-SEK 993,035,746.8493.7x-68.4x12.1x
Mon, 24 Jun 2024SEK 64.6bSEK 6.4b-SEK 862,366,054.2974.8x-74.9x10.1x
Wed, 22 May 2024SEK 53.2bSEK 6.4b-SEK 763,251,677.6071x-69.7x8.3x
Fri, 19 Apr 2024SEK 48.2bSEK 6.2b-SEK 1,040,646,287.5876.2x-46.4x7.7x
Sun, 17 Mar 2024SEK 51.3bSEK 6.2b-SEK 1,038,063,400.1178.4x-49.4x8.2x
Tue, 13 Feb 2024SEK 52.7bSEK 6.0b-SEK 906,478,242.3568.2x-58.2x8.8x
Thu, 11 Jan 2024SEK 71.9bSEK 9.5b-SEK 1,182,087,380.0069.2x-60.8x7.6x
Sat, 09 Dec 2023SEK 62.9bSEK 9.4b-SEK 1,184,547,622.0057.7x-53.1x6.7x
Mon, 06 Nov 2023SEK 53.9bSEK 9.3b-SEK 1,122,821,864.0082.7x-48x5.8x
Wed, 04 Oct 2023SEK 51.0bSEK 9.2b-SEK 1,177,266,410.00114.1x-43.3x5.5x
Fri, 01 Sep 2023SEK 51.0bSEK 9.2b-SEK 1,178,525,383.00141.2x-43.3x5.5x
Sun, 30 Jul 2023SEK 50.7bSEK 8.9b-SEK 1,414,051,886.0087.7x-35.9x5.7x
Tue, 27 Jun 2023SEK 47.3bSEK 8.4b-SEK 1,693,014,954.0078.5x-27.9x5.7x
Thu, 25 May 2023SEK 48.9bSEK 8.4b-SEK 1,693,623,432.0074.2x-28.9x5.9x
Sat, 22 Apr 2023SEK 46.0bSEK 8.0b-SEK 1,794,926,744.00100.6x-25.6x5.8x
Mon, 20 Mar 2023SEK 45.5bSEK 8.0b-SEK 1,793,560,562.0083.8x-25.4x5.7x
Wed, 15 Feb 2023SEK 46.3bSEK 7.4b-SEK 1,927,688,927.00240.2x-24x6.3x
Price to Earnings Ratio

-24x


Total Market Cap: SEK 46.3bTotal Earnings: -SEK 1,927,688,927.00Total Revenue: SEK 7.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -73.3x202420252026
Current Industry PE
  • Investors are optimistic on the Swedish Pharmaceuticals industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 8.9x is lower than the industry's current PS ratio of 9.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 10.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market2.14%
Healthcare3.10%
Pharma1.93%
Pharma1.93%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 686.502.8%
+SEK 1.1b		14.4%PE52.4x
SECARE SwedencareSEK 24.952.9%
+SEK 111.9m		-48.1%PE63.4x
DICOT Dicot PharmaSEK 0.3315.6%
+SEK 89.4m		13.4%PB46.9x
IBT B Infant Bacterial TherapeuticsSEK 49.956.3%
+SEK 39.7m		23.6%PB6.4x
FLERIE FlerieSEK 35.800.4%
+SEK 11.6m		-25.8%PS990.3x

Latest News

IBT B
SEK 49.95
Infant Bacterial Therapeutics
7D
6.3%
1Y
23.6%
ORX
SEK 28.30
Orexo
7D
-5.5%
1Y
52.2%

ORX: Higher Required Return Will Still Support Very Large Future P E Multiple

Narrative Update Analysts have trimmed their price target on Orexo to US$38.00, reflecting slightly higher discount rate assumptions and a modestly lower profit margin outlook. They are still applying a very large forward P/E multiple that keeps the fair value estimate unchanged at US$38.00.
SECARE
SEK 24.95
Swedencare
7D
2.9%
1Y
-48.1%

Big Box Expansion And Soft Chew Capacity Will Transform Long Term Pet Health Prospects

Catalysts About Swedencare Swedencare develops and sells pet health products and provides contract development and manufacturing services to animal health companies. What are the underlying business or industry changes driving this perspective?
ERMA
SEK 0.96
Enorama Pharma
7D
-37.5%
1Y
-50.8%
CAMX
SEK 686.50
Camurus
7D
2.8%
1Y
14.4%

CAMX: Obesity Data And Resubmitted NDA Will Drive Future Upside Potential

Analysts have lifted their price target on Camurus from SEK 793.71 to SEK 814.17, citing updated assumptions around revenue growth, margin potential, and a lower future P/E multiple as key drivers of the change. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly treatment and set a PDUFA target action date of 10 June 2026, following an earlier Complete Response Letter related to a third party manufacturing facility (Key Developments).
DICOT
SEK 0.33
Dicot Pharma
7D
15.6%
1Y
13.4%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?
FLERIE
SEK 35.80
Flerie
7D
0.4%
1Y
-25.8%
KDEV
SEK 0.26
Karolinska Development
7D
-10.2%
1Y
-75.8%
CESSA
DKK 19.12
Cessatech
7D
-15.6%
1Y
64.8%
ACUC
SEK 0.76
AcuCort
7D
2.0%
1Y
-9.9%
CINPHA
SEK 16.86
Cinclus Pharma Holding
7D
-2.7%
1Y
-8.1%
CLBIO
SEK 16.00
Corline Biomedical
7D
-8.0%
1Y
42.9%
KLAR
SEK 0.99
Klaria Pharma Holding AB (publ.)
7D
-15.6%
1Y
-18.3%
ENZY
SEK 1.85
Enzymatica
7D
-6.1%
1Y
17.1%

Will Enzymatica (STO:ENZY) Spend Its Cash Wisely?

Dec 20
Will Enzymatica (STO:ENZY) Spend Its Cash Wisely?
ANNX
SEK 15.90
Annexin Pharmaceuticals
7D
8.2%
1Y
-59.4%
ONCOZ
SEK 5.58
OncoZenge
7D
7.5%
1Y
8.3%